{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:25:58Z","timestamp":1788193558362,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R310-2018-3711"],"award-info":[{"award-number":["R310-2018-3711"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Library, Copenhagen University Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the involvement of calcitonin gene-related peptide (CGRP) in migraines is well-established, its specific role in investigating the aura phase, which often precedes the headache, remains largely unexplored. This study aims to instigate CGRP\u2019s potential in triggering aura, thus establishing its role in the early stages of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, non-randomized, single-arm trial, 34 participants with migraine with aura received continuous intravenous infusion of CGRP (1.5\u00a0\u00b5g\/min) over 20\u00a0min on a single experimental day. Participants were required to be free of headache and report no use of acute medications 24\u00a0h before infusion start. The primary endpoint was the incidence of migraine aura during the 12-hour observational period after the start of infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen (38%) of 34 participants developed migraine aura after CGRP infusion. In addition, 24 (71%) of 34 participants developed migraine headache following CGRP infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that CGRP could play an important role in the early phases of a migraine attack, including during the aura phase. These insights offer a new perspective on the pathogenesis of migraines with aura. They underscore the need for additional research to further explore the role of CGRP in these initial stages of a migraine attack, and potentially inform future development of therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT04592952.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01656-4","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T04:02:52Z","timestamp":1694059372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Calcitonin gene-related peptide causes migraine aura"],"prefix":"10.1186","volume":"24","author":[{"given":"Haidar M.","family":"Al-Khazali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Wiggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrim","family":"Iljazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune H\u00e4ckert","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Winther","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"1656_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol 17:954\u2013976. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"key":"1656_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M, Migraine N. Engl J Med. 2020;383:1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"key":"1656_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7","journal-title":"Lancet"},{"key":"1656_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1152\/physrev.00027.2014","volume":"95","author":"C Ayata","year":"2015","unstructured":"Ayata C, Lauritzen M (2015) Spreading Depression, spreading depolarizations, and the cerebral vasculature. Physiol Rev 95:953\u2013993. https:\/\/doi.org\/10.1152\/physrev.00027.2014","journal-title":"Physiol Rev"},{"key":"1656_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nm0202-136","volume":"8","author":"H Bolay","year":"2002","unstructured":"Bolay H, Reuter U, Dunn AK et al (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136\u2013142. https:\/\/doi.org\/10.1038\/nm0202-136","journal-title":"Nat Med"},{"key":"1656_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14737175.2021.1947797","volume":"21","author":"D Vuralli","year":"2021","unstructured":"Vuralli D, Karatas H, Yemisci M, Bolay H (2021) Updated review on the link between cortical spreading depression and headache disorders. Expert Rev Neurother 21:1069\u20131084. https:\/\/doi.org\/10.1080\/14737175.2021.1947797","journal-title":"Expert Rev Neurother"},{"key":"1656_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaneurol.2021.4678","volume":"79","author":"M Ashina","year":"2022","unstructured":"Ashina M, Goadsby PJ, Dodick DW et al (2022) Assessment of Erenumab Safety and Efficacy in patients with migraine with and without aura: a secondary analysis of Randomized clinical trials. JAMA Neurol 79:159\u2013168. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4678","journal-title":"JAMA Neurol"},{"key":"1656_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/03331024221077646","volume":"42","author":"M Ashina","year":"2022","unstructured":"Ashina M, McAllister P, Cady R et al (2022) Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2. Cephalalgia 42:696\u2013704. https:\/\/doi.org\/10.1177\/03331024221077646","journal-title":"Cephalalgia"},{"key":"1656_CR9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394:1765\u20131774. https:\/\/doi.org\/10.1016\/S0140-6736(19)32504-8","journal-title":"Lancet"},{"key":"1656_CR10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30:1179\u20131186. https:\/\/doi.org\/10.1177\/0333102410368444","journal-title":"Cephalalgia"},{"key":"1656_CR11","doi-asserted-by":"publisher","unstructured":"Karlsson WK, Ashina H, Cullum CK, Christensen RH, Al-Khazali HM, Amin FM, Ashina M (2023) REFORM Investigators. The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics. J Headache Pain 24(1):70. https:\/\/doi.org\/10.1186\/s10194-023-01604-2","DOI":"10.1186\/s10194-023-01604-2"},{"key":"1656_CR12","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1656_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1177\/0333102420981666","volume":"41","author":"A Iljazi","year":"2021","unstructured":"Iljazi A, Ashina H, Zhuang ZA et al (2021) Hypersensitivity to calcitonin gene-related peptide in chronic migraine. Cephalalgia 41:701\u2013710. https:\/\/doi.org\/10.1177\/0333102420981666","journal-title":"Cephalalgia"},{"key":"1656_CR14","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/ana.25915","volume":"88","author":"H Ashina","year":"2020","unstructured":"Ashina H, Iljazi A, Al-Khazali HM et al (2020) Hypersensitivity to calcitonin gene-related peptide in post-traumatic headache. Ann Neurol 88:1220\u20131228. https:\/\/doi.org\/10.1002\/ana.25915","journal-title":"Ann Neurol"},{"key":"1656_CR15","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/brain\/awy228","volume":"141","author":"JH Butt","year":"2018","unstructured":"Butt JH, Rostrup E, Hansen AS et al (2018) Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura. Brain 141:2943\u20132951. https:\/\/doi.org\/10.1093\/brain\/awy228","journal-title":"Brain"},{"key":"1656_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1177\/03331024221088998","volume":"42","author":"JH Butt","year":"2022","unstructured":"Butt JH, Eddelien S, Kruuse H C (2022) The headache and aura-inducing effects of sildenafil in patients with migraine with aura. Cephalalgia 42:984\u2013992. https:\/\/doi.org\/10.1177\/03331024221088998","journal-title":"Cephalalgia"},{"key":"1656_CR17","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/head.13753","volume":"60","author":"A Hougaard","year":"2020","unstructured":"Hougaard A, Younis S, Iljazi A et al (2020) Intravenous Endothelin-1 infusion does not induce aura or headache in migraine patients with aura. Headache 60:724\u2013734. https:\/\/doi.org\/10.1111\/head.13753","journal-title":"Headache"},{"key":"1656_CR18","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/brain\/awab136","volume":"144","author":"MA-M Al-Karagholi","year":"2021","unstructured":"Al-Karagholi MA-M, Ghanizada H, Nielsen CAW et al (2021) Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain 144:2322\u20132332. https:\/\/doi.org\/10.1093\/brain\/awab136","journal-title":"Brain"},{"key":"1656_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.pain.2004.05.007","volume":"110","author":"KS Afridi","year":"2004","unstructured":"Afridi KS, Kaube H, Goadsby JP (2004) Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110:675\u2013680. https:\/\/doi.org\/10.1016\/j.pain.2004.05.007","journal-title":"Pain"},{"key":"1656_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1468-2982.2004.00639.x","volume":"24","author":"G Sances","year":"2004","unstructured":"Sances G, Tassorelli C, Pucci E et al (2004) Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia 24:110\u2013119. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00639.x","journal-title":"Cephalalgia"},{"key":"1656_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/j.1468-2982.1999.019007660.x","volume":"19","author":"I Christiansen","year":"1999","unstructured":"Christiansen I, Thomsen L, Daugaard D et al (1999) Glyceryl Trinitrate induces attacks of Migraine without Aura in Sufferers of Migraine with Aura. Cephalalgia 19:660\u2013667. https:\/\/doi.org\/10.1046\/j.1468-2982.1999.019007660.x","journal-title":"Cephalalgia"},{"key":"1656_CR22","doi-asserted-by":"publisher","unstructured":"Hansen JM, Thomsen LL, Olesen J, Ashina M (2008) Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia 28(5):496\u2013505. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01559.x. Epub 2008 Mar 31","DOI":"10.1111\/j.1468-2982.2008.01559.x"},{"key":"1656_CR23","doi-asserted-by":"publisher","unstructured":"Hansen JM, Thomsen LL, Olesen J, Ashina M (2010) Coexisting typical migraine in familial hemiplegic migraine. Neurology 74(7):594\u2013600. https:\/\/doi.org\/10.1212\/WNL.0b013e3181cff79d","DOI":"10.1212\/WNL.0b013e3181cff79d"},{"key":"1656_CR24","doi-asserted-by":"publisher","unstructured":"Hansen JM, Thomsen LL, Olesen J, Ashina M (2008) Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology 71(11):841\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000325482.64106.3f","DOI":"10.1212\/01.wnl.0000325482.64106.3f"},{"key":"1656_CR25","doi-asserted-by":"publisher","unstructured":"Hansen JM, Thomsen LL, Olesen J, Ashina M (2011) Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. Headache 51(4):544\u201353. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01861.x","DOI":"10.1111\/j.1526-4610.2011.01861.x"},{"key":"1656_CR26","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1212\/WNL.0b013e3182749eed","volume":"79","author":"JM Hansen","year":"2012","unstructured":"Hansen JM, Lipton RB, Dodick DW et al (2012) Migraine headache is present in the aura phase: a prospective study. Neurology 79:2044\u20132049. https:\/\/doi.org\/10.1212\/WNL.0b013e3182749eed","journal-title":"Neurology"},{"key":"1656_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.10026","volume":"51","author":"ELH Spierings","year":"2002","unstructured":"Spierings ELH (2002) Parallel concept of migraine pathogenesis. Ann Neurol 51:139\u2013140. https:\/\/doi.org\/10.1002\/ana.10026","journal-title":"Ann Neurol"},{"key":"1656_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1526-4610.1988.hed2810655.x","volume":"28","author":"EL Spierings","year":"1988","unstructured":"Spierings EL (1988) Recent advances in the understanding of migraine. Headache 28:655\u2013658. https:\/\/doi.org\/10.1111\/j.1526-4610.1988.hed2810655.x","journal-title":"Headache"},{"key":"1656_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/s1474-4422(15)00184-2","volume":"14","author":"R Akkermans","year":"2015","unstructured":"Akkermans R (2015) Harold G Wolff. Lancet Neurol 14:982\u2013983. https:\/\/doi.org\/10.1016\/s1474-4422(15)00184-2","journal-title":"Lancet Neurol"},{"key":"1656_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000502471","volume":"104","author":"K Warfvinge","year":"2019","unstructured":"Warfvinge K, Edvinsson L, Pickering DS, Sheykhzade M (2019) The Presence of Calcitonin Gene-Related peptide and its receptors in rat, Pig and Human Brain: species differences in calcitonin gene-related peptide pharmacology. Pharmacology 104:332\u2013341. https:\/\/doi.org\/10.1159\/000502471","journal-title":"Pharmacology"},{"key":"1656_CR31","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/awq224","volume":"133","author":"O Summ","year":"2010","unstructured":"Summ O, Charbit AR, Andreou AP, Goadsby PJ (2010) Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133:2540\u20132548. https:\/\/doi.org\/10.1093\/brain\/awq224","journal-title":"Brain"},{"key":"1656_CR32","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/sj.bjp.0705807","volume":"142","author":"RJ Storer","year":"2004","unstructured":"Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171\u20131181. https:\/\/doi.org\/10.1038\/sj.bjp.0705807","journal-title":"Br J Pharmacol"},{"key":"1656_CR33","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1177\/0333102415576723","volume":"35","author":"P Pozo-Rosich","year":"2015","unstructured":"Pozo-Rosich P, Storer R, Charbit A, Goadsby P (2015) Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia 35:1298\u20131307. https:\/\/doi.org\/10.1177\/0333102415576723","journal-title":"Cephalalgia"},{"key":"1656_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0333102418774299","volume":"39","author":"LN Close","year":"2019","unstructured":"Close LN, Eftekhari S, Wang M et al (2019) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 39:428\u2013434. https:\/\/doi.org\/10.1177\/0333102418774299","journal-title":"Cephalalgia"},{"key":"1656_CR35","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1523\/JNEUROSCI.0232-19.2019","volume":"39","author":"AJ Schain","year":"2019","unstructured":"Schain AJ, Melo-Carrillo A, Stratton J et al (2019) CSD-Induced arterial dilatation and plasma protein extravasation are unaffected by Fremanezumab: implications for CGRP\u2019s role in migraine with aura. J Neurosci 39:6001\u20136011. https:\/\/doi.org\/10.1523\/JNEUROSCI.0232-19.2019","journal-title":"J Neurosci"},{"key":"1656_CR36","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/j.pain.0000000000001791","volume":"161","author":"A Melo-Carrillo","year":"2020","unstructured":"Melo-Carrillo A, Schain AJ, Stratton J et al (2020) Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood\u2013brain barrier. Pain 161:1037\u20131043. https:\/\/doi.org\/10.1097\/j.pain.0000000000001791","journal-title":"Pain"},{"key":"1656_CR37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/03331024221083544","volume":"42","author":"AM Strassman","year":"2022","unstructured":"Strassman AM, Melo-Carrillo A, Houle TT et al (2022) Atogepant \u2013 an orally-administered CGRP antagonist \u2013 attenuates activation of meningeal nociceptors by CSD. Cephalalgia 42:933\u2013943. https:\/\/doi.org\/10.1177\/03331024221083544","journal-title":"Cephalalgia"},{"key":"1656_CR38","doi-asserted-by":"publisher","first-page":"e0150334","DOI":"10.1371\/journal.pone.0150334","volume":"11","author":"MS Asghar","year":"2016","unstructured":"Asghar MS, Becerra L, Larsson HBW et al (2016) Calcitonin gene-related peptide modulates Heat Nociception in the human brain - an fMRI study in healthy volunteers. PLoS ONE 11:e0150334. https:\/\/doi.org\/10.1371\/journal.pone.0150334","journal-title":"PLoS ONE"},{"key":"1656_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-021-01365-w","volume":"23","author":"A Wiggers","year":"2022","unstructured":"Wiggers A, Ashina H, Hadjikhani N et al (2022) Brain barriers and their potential role in migraine pathophysiology. J Headache Pain 23:16. https:\/\/doi.org\/10.1186\/s10194-021-01365-w","journal-title":"J Headache Pain"},{"key":"1656_CR40","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1093\/brain\/awz199","volume":"142","author":"MA-M Al-Karagholi","year":"2019","unstructured":"Al-Karagholi MA-M, Hansen JM, Guo S et al (2019) Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain 142:2644\u20132654. https:\/\/doi.org\/10.1093\/brain\/awz199","journal-title":"Brain"},{"key":"1656_CR41","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA-M et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397:1496\u20131504. https:\/\/doi.org\/10.1016\/S0140-6736(20)32162-0","journal-title":"Lancet"},{"key":"1656_CR42","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1177\/0333102419888490","volume":"39","author":"MA-M Al-Karagholi","year":"2019","unstructured":"Al-Karagholi MA-M, Ghanizada H, Hansen JM et al (2019) Extracranial activation of ATP-sensitive potassium channels induces vasodilation without nociceptive effects. Cephalalgia 39:1789\u20131797. https:\/\/doi.org\/10.1177\/0333102419888490","journal-title":"Cephalalgia"},{"key":"1656_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nn.2475","volume":"13","author":"R Noseda","year":"2010","unstructured":"Noseda R, Kainz V, Jakubowski M et al (2010) A neural mechanism for exacerbation of headache by light. Nat Neurosci 13:239\u2013245. https:\/\/doi.org\/10.1038\/nn.2475","journal-title":"Nat Neurosci"},{"key":"1656_CR44","doi-asserted-by":"publisher","first-page":"e103929","DOI":"10.1371\/journal.pone.0103929","volume":"9","author":"R Noseda","year":"2014","unstructured":"Noseda R, Kainz V, Borsook D, Burstein R (2014) Neurochemical pathways that converge on thalamic trigeminovascular neurons: potential substrate for modulation of migraine by sleep, food intake, stress and anxiety. PLoS ONE 9:e103929. https:\/\/doi.org\/10.1371\/journal.pone.0103929","journal-title":"PLoS ONE"},{"key":"1656_CR45","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1523\/JNEUROSCI.14-10-06021.1994","volume":"14","author":"VN Kharazia","year":"1994","unstructured":"Kharazia VN, Weinberg RJ (1994) Glutamate in thalamic fibers terminating in layer IV of primary sensory cortex. J Neurosci 14:6021\u20136032. https:\/\/doi.org\/10.1523\/JNEUROSCI.14-10-06021.1994","journal-title":"J Neurosci"},{"key":"1656_CR46","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1212\/WNL.0000000000010740","volume":"95","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology 95:e2794\u2013e2802. https:\/\/doi.org\/10.1212\/WNL.0000000000010740","journal-title":"Neurology"},{"key":"1656_CR47","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.neuroscience.2011.05.035","volume":"189","author":"P-E Billot","year":"2011","unstructured":"Billot P-E, Comte A, Galliot E et al (2011) Time course of odorant- and trigeminal-induced activation in the human brain: an event-related functional magnetic resonance imaging study. Neuroscience 189:370\u2013376. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.05.035","journal-title":"Neuroscience"},{"key":"1656_CR48","doi-asserted-by":"publisher","first-page":"14204","DOI":"10.1523\/JNEUROSCI.3285-11.2011","volume":"31","author":"R Noseda","year":"2011","unstructured":"Noseda R, Jakubowski M, Kainz V et al (2011) Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci 31:14204\u201314217. https:\/\/doi.org\/10.1523\/JNEUROSCI.3285-11.2011","journal-title":"J Neurosci"},{"key":"1656_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1212\/WNL.0b013e31827f0f10","volume":"80","author":"A Hougaard","year":"2013","unstructured":"Hougaard A, Amin FM, Hauge AW et al (2013) Provocation of migraine with aura using natural trigger factors. Neurology 80:428\u2013431. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0f10","journal-title":"Neurology"},{"key":"1656_CR50","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/archneur.56.5.548","volume":"56","author":"Y Cao","year":"1999","unstructured":"Cao Y, Welch KM, Aurora S, Vikingstad EM (1999) Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol 56:548\u2013554. https:\/\/doi.org\/10.1001\/archneur.56.5.548","journal-title":"Arch Neurol"},{"key":"1656_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1212\/wnl.59.1.72","volume":"59","author":"Y Cao","year":"2002","unstructured":"Cao Y, Aurora SK, Nagesh V et al (2002) Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 59:72\u201378. https:\/\/doi.org\/10.1212\/wnl.59.1.72","journal-title":"Neurology"},{"key":"1656_CR52","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/ana.1293","volume":"50","author":"SM Bowyer","year":"2001","unstructured":"Bowyer SM, Aurora KS, Moran JE et al (2001) Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 50:582\u2013587. https:\/\/doi.org\/10.1002\/ana.1293","journal-title":"Ann Neurol"},{"key":"1656_CR53","doi-asserted-by":"publisher","first-page":"805334","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R et al (2021) Erenumab for Migraine Prevention in a 1-Year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334. https:\/\/doi.org\/10.3389\/fneur.2021.805334","journal-title":"Front Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01656-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01656-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01656-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:02:07Z","timestamp":1700391727000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01656-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1656"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01656-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"23 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of Capital Region, Denmark, and\u00a0and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"HA reports receiving personal fees from Teva outside of the submitted work. HS reports receiving personal fees from AbbVie, Teva, Lundbeck, Novartis, Eli Lilly, outside of the submitted work. FMA reports receiving personal fees from Pfizer, Teva, Lundbeck, Novartis, and Eli Lilly outside of the submitted work. MA reports receiving personal fees from AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals outside of the submitted work. MA also serves as an associate editor of Cephalalgia, an associate editor of The Journal of Headache and Pain, and an associate editor of Brain. The remaining authors report no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}